Clinical observation of docetaxel combined with cisplatin and 5-fluorouracil in the treatment of advanced gastric cancer

Objective To investigate the efficacy of weekly docetaxel(TXT),cisplatin(DDP) combined with continuous infusion of low dose fluorouraeil(FU) on advanced gastric carcinoma.Methods 36 patients with advanced gastric cancer diagnosed pathologically were enrolled into the study.The patients received docetaxel 40 mg/m2 on day 1,8;cisplatin 20mg/m2 on day 1、2,8、9,and 5-Fu 1.25g/m2 infused with an ambulatory pump on day 1、2,8、9,continuous 96h,repeated every 21 days at least 2 courses.All patients were assessable for toxicity and response to treatment.Results Three complete responses and fourteen partial responses were observed.Stable disease was observed in thirteen patients,with progressive disease in the other four patients,the overall response rate was 46.8%.Median time to progression(TTP) and median overall survival(OS)were 5.8 and 8.3 months,respectively.The one year survival rate was 15.6%.No significant difference existed between the initial and retreated patients(RR,55.5% vs 35.7%,P0.05).The most common toxicities were myelosuppression,nausea,vomiting and alopecia.The severity of these side effects were grade I-Ⅱ,and well tolerated.The grade Ⅲ-Ⅳ and hypolekocytosis were 16.7%(6/36)and 63.9%(23/36)in tota1.Conclusions The DCF(Docetaxel combined with cisplatin and 5-fluorouracil) plan is safe and effective.